Lilly’s Zepbound Beats Novo’s Wegovy in First Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Zepbound leads to more weight loss than Wegovy, new study finds
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
The Financial Express19m
Lilly’s Zepbound outshines Wegovy in weight loss head-to-head trial
Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...
Eli Lilly stock higher following surprise weight loss treatment data
Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.
Eli Lilly's stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.'s stock (LLY) rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk's Wegovy showed an average weight loss of 20.2% ...
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
devdiscourse36m
Weight Loss Battle: Zepbound Outshines Wegovy
Eli Lilly's obesity drug Zepbound proved significantly more effective than Novo Nordisk's Wegovy in a landmark trial, helping ...
Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...